Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s pharma sales surged in the second quarter, driven by heart drug Xarelto, new ophthalmic Eylea and cancer treatment Stivarga, prompting the German blue chip to raise its sales forecast for medicines this year and assert that its new oral anticoagulant probably will become profitable in 2014.
You may also be interested in...
Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division
Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.
Bayer Launches Stivarga In Malaysia And Singapore For Terminal Colorectal Cancer Patients To Prolong Survival
Bayer built upon approvals in the U.S., Europe and Japan to launch Stivarga for the first time in Southeast Asia. Well-established cancer treatment centers in Singapore and Malaysia attract patients in the region as well as far afield from the Middle East.